These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 32732618)

  • 21. De novo donor specific antibodies and patient outcomes in renal transplantation.
    DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
    Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and impact of HLA and MICA allele mismatching on donor-specific antibodies induction in kidney transplant rejection.
    Romphruk AV; Simtong P; Suntornnipat J; Sudwilai Y; Cheunta S; Chan-On C; Leelayuwat C
    Nephrology (Carlton); 2021 Oct; 26(10):833-841. PubMed ID: 34197005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The association between human leukocyte antigen eplet mismatches, de novo donor-specific antibodies, and the risk of acute rejection in pediatric kidney transplant recipients.
    Sharma A; Taverniti A; Graf N; Teixeira-Pinto A; Lewis JR; Lim WH; Alexander SI; Durkan A; Craig JC; Wong G
    Pediatr Nephrol; 2020 Jun; 35(6):1061-1068. PubMed ID: 32065279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. De novo Donor-specific Anti-human Leukocyte Antigen Antibody and Its Outcome in Pediatric Renal Transplant Recipients: A Single-center Experience in India.
    Saha A; Kapadia SF; Vala KB; Trivedi VB; Patel HV; Shah PR; Kute VB
    Saudi J Kidney Dis Transpl; 2023 Jan; 34(1):87-95. PubMed ID: 38092720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Posttransplant soluble B-cell activating factor kinetics in pediatric recipients of first kidney allograft.
    Comoli P; Quartuccio G; Cioni M; Parodi A; Nocera A; Basso S; Fontana I; Magnasco A; Sioli V; Guido I; Klersy C; Zecca M; Cardillo M; Ghiggeri GM; Ginevri F
    Transplantation; 2015 Jan; 99(1):243-9. PubMed ID: 25033258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted monitoring of donor-specific HLA antibodies following renal transplantation.
    Almeshari K; Pall A; Chaballout A; Elgamal H; Almana H; Alzayer F; Abaalkhail N; Altalhi M
    Clin Transpl; 2011; ():395-400. PubMed ID: 22755437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.
    Cooper JE; Gralla J; Chan L; Wiseman AC
    Clin Transpl; 2011; ():359-64. PubMed ID: 22755431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does a Useful Test Exist to Properly Evaluate the Pathogenicity of Donor-specific Antibodies? Lessons From a Comprehensive Analysis in a Well-studied Single-center Kidney Transplant Cohort.
    Gautier Vargas G; Olagne J; Parissiadis A; Joly M; Cognard N; Perrin P; Froelich N; Guntz P; Gachet C; Moulin B; Caillard S
    Transplantation; 2020 Oct; 104(10):2148-2157. PubMed ID: 31895344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preformed and de novo DSA are associated with T-cell-mediated rejection in pediatric liver transplant recipients requiring clinically indicated liver biopsy.
    Schluckebier D; Cousin VL; Petit LM; Belli D; Wildhaber B; Rougemont AL; Villard J; Ferrari-Lacraz S; McLin VA
    Pediatr Transplant; 2020 Feb; 24(1):e13611. PubMed ID: 31682057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deleterious Impact of Donor-Specific Anti-HLA Antibodies Toward HLA-Cw and HLA-DP in Kidney Transplantation.
    Bachelet T; Martinez C; Del Bello A; Couzi L; Kejji S; Guidicelli G; Lepreux S; Visentin J; Congy-Jolivet N; Rostaing L; Taupin JL; Kamar N; Merville P
    Transplantation; 2016 Jan; 100(1):159-66. PubMed ID: 26262501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eplet mismatch scores and de novo donor-specific antibody development in simultaneous pancreas-kidney transplantation.
    Ladowski JM; Mullins H; Romine M; Kloda D; Young C; Hauptfeld-Dolejsek V; Houp J; Locke J
    Hum Immunol; 2021 Mar; 82(3):139-146. PubMed ID: 33390268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. De novo donor-specific human leukocyte antigen antibodies early after kidney transplantation.
    Heilman RL; Nijim A; Desmarteau YM; Khamash H; Pando MJ; Smith ML; Chakkera HA; Huskey J; Valdez R; Reddy KS
    Transplantation; 2014 Dec; 98(12):1310-5. PubMed ID: 24879384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing.
    Süsal C; Wettstein D; Döhler B; Morath C; Ruhenstroth A; Scherer S; Tran TH; Gombos P; Schemmer P; Wagner E; Fehr T; Živčić-Ćosić S; Balen S; Weimer R; Slavcev A; Bösmüller C; Norman DJ; Zeier M; Opelz G;
    Transplantation; 2015 Sep; 99(9):1976-80. PubMed ID: 25769065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.
    Islam AK; Sinha N; DeVos JM; Kaleekal TS; Jyothula SS; Teeter LD; Nguyen DTM; Eagar TN; Moore LW; Puppala M; Wong STC; Knight RJ; Frost AE; Graviss EA; Osama Gaber A
    Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28658512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.
    Schinstock CA; Cosio F; Cheungpasitporn W; Dadhania DM; Everly MJ; Samaniego-Picota MD; Cornell L; Stegall MD
    Am J Transplant; 2017 Jun; 17(6):1574-1584. PubMed ID: 27977905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Problem of Subclinical Antibody-mediated Rejection in Kidney Transplantation.
    Filippone EJ; Farber JL
    Transplantation; 2021 Jun; 105(6):1176-1187. PubMed ID: 33196628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of HLA molecular level mismatching in ethnically diverse kidney transplant recipients receiving a steroid-sparing immunosuppression protocol.
    Santos E; Spensley K; Gunby N; Worthington J; Roufosse C; Anand A; Willicombe M
    Am J Transplant; 2024 Jul; 24(7):1218-1232. PubMed ID: 38403189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.
    Wiebe C; Gibson IW; Blydt-Hansen TD; Karpinski M; Ho J; Storsley LJ; Goldberg A; Birk PE; Rush DN; Nickerson PW
    Am J Transplant; 2012 May; 12(5):1157-67. PubMed ID: 22429309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammation in Early Kidney Allograft Surveillance Biopsies With and Without Associated Tubulointerstitial Chronic Damage as a Predictor of Fibrosis Progression and Development of De Novo Donor Specific Antibodies.
    García-Carro C; Dörje C; Åsberg A; Midtvedt K; Scott H; Reinholt FP; Holdaas H; Seron D; Reisæter AV
    Transplantation; 2017 Jun; 101(6):1410-1415. PubMed ID: 27163535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship among C1q-fixing de novo donor specific antibodies, C4d deposition and renal outcome in transplant glomerulopathy.
    Messina M; Ariaudo C; Praticò Barbato L; Beltramo S; Mazzucco G; Amoroso A; Ranghino A; Cantaluppi V; Fop F; Segoloni GP; Biancone L
    Transpl Immunol; 2015 Sep; 33(1):7-12. PubMed ID: 26160049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.